DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics Market, which ...
The "Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic ...
Molecular diagnostics is becoming a driving force in drug development. Applications have spread from identifying infections to include screening for cancer, hepatitis, and a variety of genetic ...
Clinical Utility of Pharmacogenomics and Genetic Testing Remains an Issue Through rapid advances in research and clinical applications, molecular diagnostics has grown from a genomic and proteomic ...
Nanopath, a point-of-care diagnostics company enabling high-quality molecular testing in minutes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device ...
IMDX has surged 158% over the past year and is trading at a new two-year high. ・Shares maintain a 100% “Buy” opinion from ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a ...
The average one-year price target for Insight Molecular Diagnostics (NasdaqCM:IMDX) has been revised to $7.14 / share. This ...
Insight Molecular Diagnostics Inc. is rated Hold due to upcoming catalysts & pending FDA submission for GraftAssureDx. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback